WALTHAM, Mass • 2024-02-27

Frost & Sullivan Recognizes BostonGene with Frost & Sullivan’s Enabling Technology Leadership Award for Revolutionizing Precision Oncology Diagnostics

5 min to read

BostonGene honored as thought leader in precision oncology, driving the evolution of personalized cancer care through integrative multi-omic diagnostic technologies

WALTHAM, Mass – February 27, 2024 –


, a leading provider of molecular and immune profiling solutions, has been awarded the

2024 Frost & Sullivan Enabling Technology Leadership Award

.The analyst firm uses a rigorous analytical process to evaluate nominees before determining the award recipient. Frost & Sullivan identifies companies that develop growth strategies based on a visionary understanding of the future and effectively address new challenges and opportunities by deploying best practices and strategic analytics across a value chain.“Frost & Sullivan recognizes that BostonGene is at the forefront of oncological innovation, exemplified by its groundbreaking progress in next-generation sequencing, digital image analysis, and immunoprofiling,” said Natalia Casanovas, Best Practices Research Analyst at Frost & Sullivan. “With a commitment to precision and excellence, BostonGene’s diagnostic technologies and approaches underscore its dedication to advancing the field of oncology, offering comprehensive solutions that redefine the landscape of personalized cancer care.”From pioneering first-in-human clinical trials to strategic partnerships addressing specific cancer types, BostonGene’s multidisciplinary approach demonstrates its commitment to tailoring treatment strategies and elevating patient care. Trailblazing innovations in cancer care technologies position BostonGene as an industry leader. BostonGene is reshaping the landscape of precision medicine by strategically focusing on novel research and impactful solutions, expanding personalized medicine beyond the limits of oncology.“We are honored to receive this award recognizing our multi-omics approaches and AI/ML-enabled solutions, which are becoming industry standards for biomarker analysis, patient stratification in drug development and accelerating innovation. These technologies are driving a transformative shift, fostering the next generation of diagnostic approaches in precision oncology, “said Andrew Feinberg, President and CEO of BostonGene.

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin Keleher O'Reilly

Senior Director